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Editors-in-Chief
Jan Tornell – AstraZeneca, Sweden
Andrew McCulloch – University of California, SanDiego, USAAn increased lifespan comes with an associated in-
crease in disease incidence, and is the major risk factor
for age-related diseases. To face this societal challenge
search for new treatments has intensiﬁed requiring
good preclinical models, whose complexity and accu-
racy is increasing. However, the inﬂuence of ageing is
often overlooked. Furthermore, phenotypic assess-
ment of ageing models is in need of standardisation
to enable the accurate evaluation of pre-clinical inter-
vention studies in line with clinical translation.
Introduction
What has become clear over the last decade or so is that the
concept that ageing is simply an accumulation of damage and
physiological systems ‘wearing out’ are simplistic. Ageing
processes are major contributors to the development of
age-related disease [1–4] and can be modified, by interven-
tions and genetically, across a range of organisms. Ageing can
also impact on efficacy of disease treatments through changes
in drug pharmacokinetic (PK) and pharmacodynamics (PD),
which exerts its effects on therapeutic regimens. Whilst there
is no unified ‘theory of ageing’ we are learning more and more
about the physiological processes and the consequences of
ageing and it is clear that this is a factor we should incorporate
into modelling of disease and in preclinical studies. Within
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several challenges including; increased frailty in older ani-
mals, limiting the number and types of assessment possible,
increased difficulty in interpreting signs of ill health or
humane endpoints, variability due to the differential rates
of ageing in individual organisms, and the influence of
environmental factors. In addition, models may need to be
very complex to reproduce aspects of the multiple patholo-
gies associated with frailty and multimorbidity. For this
reason the standardisation of phenotypic assessment of
animals and standardisation of study design is more critical
than ever.
The importance of ``ageing” in modelling age-related
diseases
Mice are used to study ageing itself. For a review of how mice
have been used in some studies of the ageing process please
refer to Vanhooren and Libert [5]. Many disease studies do
routinely incorporate ageing into their design, but many
disease areas also use genetically modified organisms that
have an early onset and/or acute phenotype when the disease
burden is primarily a chronic or age-related condition. Exam-
ples of such models are the Apoe knockout mice [6,7] for the
study of atherosclerosis and the ob/ob diabetic mouse [8].
While both have advanced our understanding of disease,
these are extreme examples of disease with a rapid onset
and do not necessarily recapitulate all aspects of human-related disease, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
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processes underlying age-related disease it is clear that we
cannot model the complete range of phenotypes observed in
patients in a single model, and it would be naı¨ve to expect
this to be so. We must therefore ensure there is a clear
comprehension of the limitations and drawbacks of individ-
ual models as well as their similarities to symptoms observed
in patients. Indeed the term model is often applied too freely
and it should be acceptable to state that these are genetically
modified organisms that aid our understanding of disease
rather than labelling everything with moniker of model. This
is exemplified by the recently published comment on mouse
lines used to study amyotrophic lateral sclerosis (ALS) [9].
Although not an age-related disease it highlights the need for
a complete understanding of disease in models and patients.
As emphasised in this article, a commonly used ‘model’ of
ALS, TDP-43 mutant mice, were found to die of a bowel
obstruction rather than the progressive muscle atrophy seen
in patients, thus severely limiting its usefulness in pre-clinical
studies [10]. This work drives home the importance of under-
standing why data does not translate from putative disease
models. It is not sufficient to say that mouse lines are not
suitable; we must investigate if and why they are not suitable
and understand any limitations, which may indeed ultimate-
ly aid our understanding of disease pathogenesis.
The rapid nature of the disease reproduced in some of these
models also means there is also a limited window of oppor-
tunity for testing therapeutic interventions. In addition,
because of the lack of an ageing physiology in such models,
the influence of age on other aspects of therapy such as PK
and PD are missing [11]. Drug toxicity is also a major problem
in drug development and a significant proportion of this
toxicity can be attributed to mitochondrial toxicity [12,13].
With ageing there is an accumulation of mitochondrial
mutations and a concomitant decline in mitochondrial func-
tion [14,15], which could therefore sensitise the aged to toxic
side-effects of drugs. Without proper pre-clinical testing in
age–appropriate disease models this toxicity may go unno-
ticed. Even then mouse lines per se may have limitations as
there may be differences between mitochondrial ageing be-
tween mice and humans [16]. Effectively, therapies are being
tested in a worst case scenario in such models where there is a
rapid and aggressive disease in young organisms rather than
the chronic progression seen in older patients. As our under-
standing of disease in models and patients progresses, so we
must refine our models accordingly. The cost of using ageing
models in preclinical testing may be more than that currently
encountered but these are insignificant when compared to
the cost of failed clinical trials.
Using mice to study ageing, age-related diseases
As we age the risk of disease increases so surely the best
murine model of age-related disease is an old mouse? WhilstPlease cite this article in press as: Bellantuono I, Potter PK. Modelling ageing and age
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mice simply by ageing mice those such as cataracts, sarcope-
nia, cancer, and tissue dysfunction is what is mostly observed
in ageing mice. Therefore there is still a need for age-appro-
priate models of individual disease to recapitulate more
complex aspect of age-related diseases. This is because age
and age-related disease are not overlapping but rather can be
seen as two parts of a multistep process [17] whereby ageing is
the first step, leading to loss of tissue reserve and homeostasis
and increased chances of developing one or more age-related
diseases. Accumulation of multiple diseases and age-related
loss of functions can result in frailty. Mechanisms of ageing
such as chronic inflammation, senescence are interlinked and
thought to exacerbate many age-related diseases such as
atherosclerosis, neurodegeneration, and osteoarthritis [18].
Chronic inflammation can arise from obesity, with adipose
tissue being an active inflammatory tissue [19], and as a result
of cellular senescence whereby senescent cells release pro-
inflammatory cytokines; the senescence associated secretory
profile (SASP). In a model of chronic inflammation Jurk et al.
demonstrated that persistent inflammation can in turn ac-
celerate ageing via telomere dysfunction and cellular senes-
cence [20]. However, not all patients get the same diseases in
the same order. This is because there are other factors such as
genetic components associated with specific pathways which
contribute to susceptibility to disease. Consequently to push
forward with personalised medicine we must understand the
specific pathways contributing to disease. Specific models of
disease will help our understanding of the specific pathways
involved in individual pathologies, how they interact with
the ageing process, and will also assist in the identification of
disease biomarkers that predict later disease.
Using mice as models to improve age-related health
outcomes
A key aim of ageing research is to translate this into beneficial
interventions to reduce the burden of age related disease. An
increase in longevity has already been shown to result in an
improved healthspan [21]. However, longevity is not neces-
sarily the best readout when considering disease parameters;
an organism may live longer but still suffer from chronic
diseases or disease may simply be delayed. Health span,
defined as time free of diseases, is now considered a better
measurement of the outcome of interventions and the main
goal of ageing research is to contract the period of morbidity
before death rather than just simply increase lifespan[22]. A
recent study on the effect of rapamycin, a dietary restriction
mimetic, demonstrated similar health benefits to dietary
restriction but without a concomitant increase in longevity
[23]. Whilst beneficial outcomes have been demonstrated
from modulating ageing processes, this does not necessarily
mean there is a generalised health benefit affecting all age-
related diseases. Resveratrol treatment of mice on a high-related disease, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
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marily due to a reduction in the incidence of pathologies
associated with cardiopulmonary distress [23]. This is also
underscored by a recent study by Neff et al. [24] who carried
out an extensive phenotypic analysis of rapamycin treated
mice to determine the influence of this treatment, known to
promote longevity even when treatment begins late in life
[25], on a range of disease phenotypes. Their conclusion was
that although there was a significant increase in longevity
and healthspan, this was primarily due to the reduction in
one disease, cancer. Other beneficial effects of rapamycin
occurred in young mice and therefore may not be directly
related to ageing processes. Whilst the interpretations of
these data [26] have been debated this study shows how
critical thorough, and indeed longitudinal, phenotyping is
to fully elucidate an age-related phenomenon.
As with all research reproducibility is critical to advancing
research findings into the clinic, and one of the major con-
tributing factors to the interpretation of data is standardisa-
tion of protocols. This is highlighted two major studies on
caloric restriction (CR). These parallel studies on the effect of
restricting CR have not resulted in a definitive conclusion as
to the beneficial results of CR with the question remaining
whether we are seeing the benefits of a healthier diet or a true
beneficial effect of CR [27]. The data from the two macaque
studies is none the less useful and informative and may
indicate how different CR strategies can benefit different
patient groups, but these studies are an example of how
differences in protocols can result in profound differences
in results, and that meta data such as diet, genetic back-
ground, and housing conditions should all be included in
study design. There is further discussion on whether the
benefits of caloric restriction in mice are universal [28].
The crux of the problem is similar to that encountered in
the primate studies; is caloric restriction truly influencing the
progress of ageing or is it simply treating the consequences of
obesity [29]? Laboratory mice are quite sedentary and have a
rich diet ad libitum so tend to become obese, especially as they
age [30] and the increases in longevity and health span could
simply represent a ‘healthier lifestyle’ rather than a true
influence on the ageing process. Key to this is the correct
reporting of detailed metadata including such things as body
composition, genotype, diet, and age of mice, all of which
have been shown to influence the outcome of caloric restric-
tion studies. Inbred strains varying considerably in life span
and disease susceptibility and as such some programmes
utilise mixed backgrounds [31] and reviewed in [5]) to better
represent the mixed genetic background present in patients.
The use of complex strains does severely restrict the use of
genetic modifications as these modifications may have to be
introduced onto several strains or necessitate additional
breeding steps. The NIA funded intervention testing pro-
gramme makes every effort to standardise procedures acrossPlease cite this article in press as: Bellantuono I, Potter PK. Modelling ageing and age
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The National Centre for the Replacement, Refinement and
Reduction of Animals in Research (NC3Rs) have begun to
address this by developing the ARRIVE guidelines to stan-
dardise reporting of animal research [32]. With the added
systemic effects of ageing and the amplifying nature of ex-
tended studies it is even more critical that protocols and
metadata are recorded in detail and made available to the
community. Beyond standardisation of the phenotyping and
housing conditions of the test mice it is also likely that we will
have to consider other metadata such as health status an age
of the mice used to breed test cohorts as there are clear
transgenerational effects of diet and body composition on
the health outcomes of offspring, particularly affecting me-
tabolism (reviewed in [33]). The recently instigated Mouse-
AGE cost action (http://www.cost.eu/COST_Actions/bmbs/
BM1402) has the stated aim of developing such standardised
protocols and methodologies for use in ageing studies.
Models of multimorbidity
Whilst mechanistic studies and delivery of interventions
have been focused on individual diseases, over 60% of people
aged over 65s have more than one disease at the same time
and more than 20% have 5 or more [34]. Multimorbidity is
the major challenge of the ageing population leading to
reduced functional status, higher mortality, a poorer quality
of life, and is the major expenditure of national healthcare
budgets [35–37]. We know that the presence of one disease
significantly increases the risk of developing another disease
[38]. However, in studies to-date attempts to identify clusters
of diseases occurring together with a higher frequency, other
than by chance have yielded inconsistent results [39–41].
This is most likely due to the lack of standardisation, partic-
ularly the classification of the type and the number of diseases
considered in the definition of multimorbidity. In addition,
many studies have not been sufficiently powered to be con-
clusive. Therefore to better understand the pathophysiology
of multimorbidity we need better clinical and preclinical
studies.
Preclinical in vivo studies are very useful to develop a
mechanistic understanding of the pathogenesis of associated
diseases and to test interventions targeting multimorbidity as
a whole. They rely on well characterised animal models,
which should be able to develop progressive and time de-
pendent diseases in later stages of life. This is very difficult to
achieve at present. An example is described by the efforts of
the Animal Models of Diabetic Complications Consortium
(AMDCC). Diabetes is often associated with increased risk of
cardiovascular disease [42,43]. The consortium aimed to de-
velop new animal models that closely mimicked the human
complications of diabetes, including cardiovascular disease.
Epidemiological data has indicated that diabetes increases-related disease, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
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arising independently of hypertension and coronary artery
disease [43]. Diabetic cardiomyopathy (DCM) is defined pri-
marily by diastolic dysfunction and hypertrophy in the left
ventricle, leading to heart failure [44,45]. Indeed ob/ob and
db/db diabetic mice develop cardiac hypertrophy, with con-
tractile disturbances and sometimes increased chamber stiff-
ness [46,47]. However, the development of CVD following
atherosclerosis is more frequent in diabetic patients than
CMD but mice are in general resistant to the development
of atherosclerosis, mainly because of differences in lipopro-
tein metabolism [48,49]. Even after being fed with very high
fat diets for 12 months, animals only develop early signs of
atherosclerosis. Genetic modifications such as those in the
ApoE/mouse or the low density lipoprotein (LDL) receptor-
–deficient mouse have been required to obtain atherosclerot-
ic lesions [49–51]. However, crossing of ob/ob or db/db mice
with ApoE/ or on LDLR/ mice alone or in combination
[52,53] resulted in large increases in plasma lipid levels,
which is not a feature of the human disease and makes it
very difficult to dissect the individual contributions of hy-
perglycemia and hyperlipidemia in relation to the formation
of atherosclerotic plaques. In addition one hallmark of ath-
erosclerosis, present also in patients with type 2 diabetes is
endothelial dysfunction, whose development precedes ath-
erosclerosis and is characterised by accumulation of DNA
damage and senescence [54,55]. However, this feature seems
to be seen only in the aortas of aged Apoe/ mice [56]. No
such impairment is seen in C57BL/6J mice at any age, sug-
gesting that a combination of genetic defect and age may be
required to reproduce the full vascular phenotype. Interest-
ingly, when ApoE/ mice were inter-crossed with 4th gen-
eration (G4) TERC/ mice to accelerate ageing and
challenged with a high cholesterol high fat diet, the mice
developed less atherosclerotic lesions compared with G4
TERC+/+ ApoE2/ mice [57]. In addition the atherosclerotic
plaques were morphologically in a less advanced stages of
development [57], suggesting that there are specific mecha-
nisms of ageing underlining senescence and endothelial
dysfunction and absence of telomerase activity is not in-
volved in this process and seems to have a protective effect
for atherosclerotic disease.
This example shows how complex the generation of mod-
els of associated pathologies can be. It needs an in depth
knowledge of the pathogenesis in humans and generation of
multiple crosses of genetically modified mice. These crosses
needs to be thoroughly characterised to fully appreciate
which aspect of the associated diseases they reproduce and
what are their limitations. The notion that progeric mice may
serve as model of multimorbidity just for the very fact that
they present with accelerated ageing features is therefore
simplistic. Each model requires a longitudinal phenotypic
and rigorous pathologic analysis to determine the temporalPlease cite this article in press as: Bellantuono I, Potter PK. Modelling ageing and age
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life, together with mechanistic causal links which explain the
development of the comorbidities.
Assessing frailty
In the last 50 years human life expectancy has been increas-
ing every year mainly due to improved management
of chronic, age-associated diseases (WHO, global health
and ageing, http://www.who.int/ageing/publications/
global_health/en/). However, life health expectancy, i.e.
the number of years in one’s life free of disease, has only
increased by half compared to the increase in life expectancy,
with the result that people live longer but suffer from an
increased burden of disease and ultimately become frail [58].
The term ‘‘frailty’’ can be described as progressive accumula-
tion of deficits across multiple systems with decreased resil-
ience and resistance to stressors, causing vulnerability to
adverse outcomes. Half of over 80 years old in the US is
considered frail with poor quality of life and high costs for
social and healthcare [58]. Therefore interventions which
address frailty are urgently required. However, the transla-
tional path for the testing of interventions for frailty is not
well defined to-date. For the approval of any new drug to be
tested in patients the disease to be treated needs to be clearly
defined and the definition has to be agreed at the interna-
tional level, appropriate animal models needs to be available
with a set of suitable measurements, which can detect
improvements meaningful to patients.
At present there is not a commonly agreed definition of
frailty, which is accepted by the regulators such as European
medicinal Association (EMA) or the Food and Drug Adminis-
tration (FDA). In patients a Frailty Index has been successfully
applied to measure frailty and predict outcomes [59] and
similar studies in mice have also identified useful parameters
in gauging the overall health of an individual animal [60,61].
Parks et al. demonstrated that easily measured parameters
resulted in a Frailty Index that correlated closely with more
detailed measurements of cardiac dysfunction, a key disease
of ageing [61]. Frailty was measured as how many standard
deviations the individual mice varied from a reference range
established using an adult, rather than aged, population and
the cumulative score was used to determine the overall frailty
of the mice. Interestingly although in this study they initially
employed 31 parameters in their study as few as 8 parameters
were sufficient to establish a Frailty Index. This Index was
further developed to utilise parameters that can be measured
easily in the majority of laboratories and requires little spe-
cialist equipment. Another index used parameters measured
in patients to more directly correlate frailty in mice and
humans [60]. However, it is unclear whether these indices
are sufficiently sensitive to measure improvement following
interventions, and whether these improvements translate in
improved quality of life for the patients. One way forward is-related disease, Drug Discov Today: Dis Model (2017), http://dx.doi.org/10.1016/j.
Vol. xxx, No. xx 2017 Drug Discovery Today: Disease Models |
DDMOD-459; No of Pages 6to focus on patients with a specific disease that is strongly
associated with frailty, such as cancer cachexia and use this as
an initial case to establish models and measurements suitable
for drug testing which then can be translated in phase I
clinical trial in patients. Cancer cachexia has several of the
features of frailty with loss of weight and muscle mass [62],
loss of resilience. Models of cancer cachexia may be recapitu-
lated by using xenograft models in ageing mice rather than in
young animals better reflecting the feature of the disease in
humans. There are xenograft models, which are slow growing
and can be treated with multiple rounds of chemotherapy
over a long period of time [63,64]. They are used to study the
development of resistance to chemotherapeutic agents. They
would represent an excellent model to assess the onset of
frailty using one of the frailty indexes available and to test
whether they are sufficiently sensitive to detect improvement
in performance following interventions, particularly in the
case with geroprotectors such as rapamycin or metformin.
New approaches to develop models of age-related
disease
Given the wide ranging impact ageing has on almost every
physiological system, and the implications this has for dis-
ease, it is essential we build in an ageing component to the
analysis of disease into our models. There is no doubt at all of
the contributions that model organisms have made to our
understanding of disease but to provide a better understand-
ing of disease and ageing, and also to improve the translation
of therapies from preclinical studies to bedside, ageing and its
effects will have to be factored into many studies [65]. Phe-
notype-driven screens are discovery platforms that associate
novel genes with phenotypes and identify novel functions of
known genes. They have been successful across a range of
disease areas and indeed, with the inception of the Interna-
tional Mouse Phenotyping Consortium (IMPC) (http://www.
mousephenotype.org/), have now attained a global scale. The
advantages of such approaches are standardised protocols,
defined environmental conditions, a wide range of pheno-
typing data, and stable genetic backgrounds. At MRC Harwell
we have undertaken the first large-scale phenotype driven
screen to incorporate ageing as a challenge to identify genes
and pathways that result in age-related disease. The pro-
gramme is described in detail elsewhere [66] but briefly this
is an ENU (N-ethyl-N-nitrosourea) based mutagenesis pro-
gramme [67] where pedigrees of mice are aged to 18 months
and phenotyped across a range of platforms. Even though this
programme is in its early stages a number of age-related
phenotypes have been identified across a range of disease
areas including hearing, vision, osteoarthritis, neurodegen-
eration, and renal disease. These models are being charac-
terised in detail and will be described elsewhere but to date
over 100 phenotypes have been identified with a quarter of
these not detected until six months or later. Several of thePlease cite this article in press as: Bellantuono I, Potter PK. Modelling ageing and age
ddmod.2017.07.005earlier mutations also have late onset additional phenotypes
or progressed as a chronic condition. From a total of 16
cloned mutations identified to date that result in an age-
related phenotype 15 revealed a novel gene function or
associated a gene with a phenotype for the first time. These
mutant lines provide preliminary support for the concept of
an ageing challenge to reveal novel gene function gene
function. An age-challenged pipeline has now been added
to the latest phase of the IMPC.
Conclusions
With age-related disease we are facing a complex problem and
simple models will not suffice. It is likely that multiple,
complex models will be required in future studies, and that
a convergence in study design is required; including ageing
when studying disease and a greater range of phenotyping to
assess health/disease/frailty/multimorbidity. Furthermore a
standardised approach to protocols employed in the study of
ageing and disease is required which may include a range of
mouse lines and metadata on the health status and age of
dams and sires of the offspring employed in these studies.
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